| Autor: |
Blackledge GR; AstraZeneca Pharmaceuticals, Medical Oncology, Alderley House, Alderley Park, Macclesfield, Cheshire SK10 4TF, UK. george.blackledge@astrazeneca.com |
| Jazyk: |
angličtina |
| Zdroj: |
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2005 Oct; Vol. 41 (15), pp. 2210-2. Date of Electronic Publication: 2005 Jan 07. |
| DOI: |
10.1016/j.ejca.2004.11.020 |
| Abstrakt: |
The number of new agents being developed for the treatment of cancer has, over the past 10 years, increased dramatically which has resulted in increased interactions between the pharmaceutical industry that discover and develop most new agents and investigators in academic institutions, hospitals and office practices. This close interaction has inevitably led to a number of issues being identified on both sides and this paper will attempt to identify some of these and propose solutions. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect